Cargando…
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint
INTRODUCTION: Identifying clinical measures that track disease in the earliest stages of frontotemporal lobar degeneration (FTLD) is important for clinical trials. Familial FTLD provides a unique paradigm to study early FTLD. Executive dysfunction is a clinically relevant hallmark of FTLD and may be...
Ejemplares similares
-
Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration
por: Staffaroni, Adam M., et al.
Publicado: (2020) -
Nonlinear Z-score modeling for improved detection of cognitive abnormality
por: Kornak, John, et al.
Publicado: (2019) -
Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration
por: Olney, Nicholas T., et al.
Publicado: (2020) -
Rates of lobar atrophy in asymptomatic MAPT mutation carriers
por: Chen, Qin, et al.
Publicado: (2019) -
Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers
por: Chen, Qin, et al.
Publicado: (2019)